280111-50-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzyl 4-(2-(tert-butoxycarbonyl)hydrazinyl)piperidine-1-carboxylate is used as a precursor in the synthesis of various pharmaceuticals for its unique structural features and reactivity. Its functional groups can be selectively modified to produce a wide range of derivatives with potential biological and medicinal applications.
Used in Organic Synthesis:
In the field of organic synthesis, Benzyl 4-(2-(tert-butoxycarbonyl)hydrazinyl)piperidine-1-carboxylate is used as a building block due to its stability and ease of handling. Its versatile functional groups allow for the creation of diverse chemical compounds, making it a valuable component in the development of new organic compounds.
Used in Fine Chemicals Production:
Benzyl 4-(2-(tert-butoxycarbonyl)hydrazinyl)piperidine-1-carboxylate is also utilized in the production of fine chemicals, where its unique structure and reactivity contribute to the synthesis of high-quality specialty chemicals for various industries, including fragrances, flavors, and agrochemicals.

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 870-46-2 t-butoxycarbonylhydrazine 
• 501-53-1 benzyl chloroformate 
• 863560-00-3 benzyl 4-(2-(tert-butoxycarbonyl)hydrazono)piperidine-1-carboxylate 

Downstream Products

• 1079396-31-8 benzyl 4-(4-chloro-1H-pyrazolo[3,4-d]|pyrimidin-1-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

A novel and efficient synthesis of 2,5-substituted 1,2,4-triazol-3-ones

A novel procedure for preparing 1,2,4-triazol-3-ones is described. Various alkyl, aryl, and heterocyclic groups were introduced successfully at both the N2 and C5 positions. The triazolone ring was constructed through an intramolecular cyclization of a novel acyclic precursor, which in turn was synthesized by treating a mono protected hydrazine with an acyl isocyanate. Under conditions that remove the hydrazine protecting group, the intramolecular cyclization occurs rapidly, to deliver the 2,5-substituted 1,2,4-triazol-3-ones in excellent yields (79-99%) without column purification.

ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF

Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Compound capable of degrading BTK kinase as well as preparation method and pharmaceutical application of compound

The invention relates to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, as well as an intermediate and preparation method of the compound, and application of the compound in BTK related diseases such as tumors or autoimmune system diseases. And B-L-K (I).

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

PI3K (DELTA) SELECTIVE INHIBITORS

Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3Kδ activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.

Discovery of a tetrahydropyrimidin-2(1 H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor

Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c] imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.

[6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n2, n3, n4, A, B, D, E, G, J, Y, R1 and R2 are defined herein.

4-SUBSTITUTED PIPERIDINE DERIVATIVES

Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.